Walsh-McMonagle D, Green D
Department of Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago and Northwestern University Medical School, Illinois 60611, USA.
Cancer. 1997 Aug 15;80(4):649-55.
Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin.
Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed.
All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy.
Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder.
游走性血栓性静脉炎是约11%癌症患者发病的主要原因。血栓形成可能早于恶性肿瘤出现，且血栓患者对华法林的反应通常较差。
本文描述了4例患有广泛血栓形成和癌症的患者。分别对这些患者皮下注射低分子量肝素依诺肝素5、6、26和27个月。对有关特鲁索综合征治疗的文献进行了综述和分析。
所有4例患者在接受低分子量肝素急性治疗及随访期间均未发生静脉血栓栓塞。先前发表的研究表明，低分子量肝素治疗的死亡率低于标准肝素治疗。
进一步研究评估低分子量肝素预防和治疗与恶性肿瘤相关的血栓栓塞的安全性和有效性，可能会降低这种疾病患者的发病率，提高生活质量。
